Last updated: August 1, 2026
Cabotegravir sodium is the active pharmaceutical ingredient in ViiV Healthcare’s long-acting HIV products: Cabenuva for treatment of established HIV-1 infection and Apretude for pre-exposure prophylaxis. Clinical data support high efficacy when injections are administered on schedule. Commercial growth is constrained by injection logistics, missed-dose management, clinic capacity, reimbursement, and competition from oral generics and longer-acting agents.
Cabotegravir has two principal commercial roles:
| Product |
Indication |
Administration |
Regulatory status |
| Cabenuva |
HIV-1 treatment in virologically suppressed adults and certain adolescents |
Intramuscular cabotegravir plus rilpivirine every month or every two months |
FDA-approved |
| Apretude |
HIV-1 pre-exposure prophylaxis |
Intramuscular cabotegravir every two months after initiation doses |
FDA-approved |
| Vocabria |
Oral cabotegravir lead-in or short-term oral therapy with rilpivirine in selected markets |
Oral tablet |
Approved in the U.S. and other jurisdictions for specified use |
ViiV Healthcare, majority-owned by GSK with Pfizer and Shionogi interests, controls the principal global commercial franchise.
What is cabotegravir sodium and how is it used?
Cabotegravir is an integrase strand transfer inhibitor. The sodium salt is used in the injectable and oral pharmaceutical products. It inhibits HIV-1 integrase, blocking integration of viral DNA into the host-cell genome.
Cabotegravir has a long effective half-life after intramuscular administration. The long pharmacokinetic tail creates both an adherence advantage and a resistance-management risk. Patients who discontinue injections without alternative antiretroviral therapy can remain exposed to declining, subtherapeutic drug concentrations.
Cabenuva combines cabotegravir with rilpivirine, a non-nucleoside reverse transcriptase inhibitor. The regimen is intended for patients who have achieved virologic suppression and have no known or suspected resistance to either component.
Apretude is used for HIV prevention in adults and adolescents weighing at least 35 kilograms. The product requires HIV testing before each injection because administration during undiagnosed infection can promote resistance.
What clinical trials support cabotegravir sodium?
Cabenuva treatment trials
The principal treatment evidence came from the ATLAS, FLAIR and ATLAS-2M trials.
| Trial |
Population |
Key finding |
| FLAIR |
Adults switching from oral therapy after initial suppression |
Monthly cabotegravir plus rilpivirine maintained noninferior virologic suppression compared with continued oral therapy |
| ATLAS |
Virologically suppressed adults on oral therapy |
Monthly injections were noninferior to standard oral treatment |
| ATLAS-2M |
Virologically suppressed adults |
Every-two-month dosing was noninferior to monthly dosing at the primary endpoint |
| SOLAR |
Adults switching from daily oral bictegravir/emtricitabine/tenofovir alafenamide |
Two-month Cabenuva maintained suppression and supported patient preference for long-acting treatment |
In ATLAS and FLAIR, the proportion of patients with HIV-1 RNA of at least 50 copies/mL at the primary endpoint was low in both treatment groups. ATLAS-2M established the commercial importance of two-month dosing, reducing the number of annual clinic visits relative to monthly administration.
The main treatment limitations are pre-existing resistance, active hepatitis B infection without separate hepatitis B therapy, missed injections, injection-site reactions and the need for reliable follow-up.
Apretude prevention trials
Apretude’s approval was based primarily on HPTN 083 and HPTN 084.
| Trial |
Participants |
Comparator |
Result |
| HPTN 083 |
Approximately 4,500 cisgender men and transgender women who have sex with men |
Daily oral tenofovir disoproxil fumarate/emtricitabine |
Cabotegravir reduced incident HIV infection by about 66% compared with daily oral PrEP in the primary analysis |
| HPTN 084 |
Approximately 3,200 cisgender women in sub-Saharan Africa |
Daily oral tenofovir disoproxil fumarate/emtricitabine |
Cabotegravir reduced incident HIV infection by about 89% compared with daily oral PrEP in the primary analysis |
The prevention data showed a major efficacy advantage over oral therapy in trial settings, but the commercial outcome depends on implementation. Apretude requires an initiation injection, a second injection one month later and injections every two months thereafter. Late injections materially increase clinical risk.
Ongoing and recent development activity
Cabotegravir development has shifted from basic efficacy to implementation, expanded populations and dosing optimization.
Key areas include:
- Pediatric and adolescent treatment through international pediatric HIV networks.
- Long-acting treatment in patients with adherence challenges.
- Real-world studies of injection scheduling, missed appointments and oral bridging.
- Implementation studies in public-health and community-clinic settings.
- Evaluation of cabotegravir in combination strategies for populations not fully represented in registrational trials.
- Pharmacokinetic studies involving pregnancy, body weight, drug interactions and injection-site administration.
The most important clinical question is no longer whether cabotegravir can suppress or prevent HIV. The commercial question is whether healthcare systems can deliver scheduled injections at scale.
How effective is cabotegravir compared with oral HIV therapy?
Cabotegravir has demonstrated noninferior treatment efficacy and superior prevention efficacy against the oral comparator used in HPTN 083 and HPTN 084. The clinical benefit is strongest for patients who struggle with daily pill adherence.
| Attribute |
Cabotegravir long-acting therapy |
Daily oral therapy |
| Dosing frequency |
Monthly or every two months for treatment; every two months for PrEP |
Daily |
| Adherence burden |
Appointment adherence |
Daily medication adherence |
| Resistance risk |
Elevated if injections are missed without oral cover |
Related to missed daily doses and drug half-life |
| Privacy |
Reduced daily pill visibility |
May expose medication use |
| Clinic burden |
High |
Lower |
| Storage and administration |
Requires trained injection provider and cold-chain handling for some presentations |
Pharmacy dispensing and patient self-administration |
| Injection reactions |
Common, generally mild to moderate |
Not applicable |
| Hepatitis B activity |
Cabotegravir has no hepatitis B treatment activity |
Tenofovir/emtricitabine provides hepatitis B activity |
Cabenuva is not a universal replacement for oral therapy. Patients with unstable engagement in care may be difficult to manage because missed injection visits can create prolonged pharmacokinetic exposure without a fully suppressive regimen.
What is the FDA regulatory status of cabotegravir sodium?
The FDA approved Cabenuva in January 2021 for treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen, have no history of treatment failure and have no known or suspected resistance to cabotegravir or rilpivirine.
The FDA approved Apretude in December 2021 for HIV-1 PrEP in adults and adolescents weighing at least 35 kilograms who are HIV-negative.
Important regulatory characteristics include:
- Cabenuva can be administered monthly or every two months, depending on the approved regimen and patient history.
- Apretude requires HIV testing before each injection.
- Oral cabotegravir may be used as an optional lead-in in certain treatment and prevention settings, but injectable initiation is central to the product value proposition.
- Labels contain detailed instructions for planned and unplanned missed injections.
- FDA safety information emphasizes hypersensitivity reactions, hepatotoxicity, injection-associated adverse events and the risk of resistance if infection is not detected promptly.
The products are listed in FDA regulatory databases and remain protected by ViiV intellectual property covering cabotegravir, formulations, dosing schedules and therapeutic use.
What patents protect cabotegravir sodium?
The cabotegravir estate includes several layers:
- Compound patents covering cabotegravir and related integrase inhibitors.
- Salt and crystalline-form protection involving cabotegravir sodium.
- Injectable formulation patents covering long-acting nanosuspensions and depot delivery.
- Combination patents covering cabotegravir with rilpivirine.
- Method-of-use patents covering HIV treatment and HIV prevention.
- Dosing patents covering monthly and two-month injection schedules.
- Manufacturing and particle-engineering know-how supporting consistent injectable performance.
The most commercially important barriers are expected to be the long-acting injectable formulation, manufacturing process and dosing-regimen claims rather than the active pharmaceutical ingredient alone. Generic cabotegravir sodium would not automatically provide a substitute for the approved long-acting injectable product.
For Cabenuva, a competing product would also need to address rilpivirine or develop a legally and clinically substitutable regimen. For Apretude, a generic injection would need to satisfy complex pharmaceutical-equivalence, device, manufacturing and clinical requirements.
Patent term extensions, pediatric exclusivity, settlement agreements and jurisdiction-specific claim scope can change practical launch dates. Orange Book status, patent certifications and Paragraph IV litigation should be reviewed separately for each dosage form and jurisdiction.
When does cabotegravir lose exclusivity?
The commercial exclusivity timeline is product-specific rather than determined by a single cabotegravir sodium patent.
Key timing factors are:
- The earliest compound patent expiration.
- Patent term adjustment and patent term extension.
- U.S. five-year new chemical entity exclusivity, if applicable to the relevant product.
- Three-year exclusivity for new clinical investigations.
- Pediatric exclusivity.
- Injectable formulation and dosing patents.
- Regulatory approval timing for generic or follow-on products.
- Patent litigation and settlement terms.
A direct generic challenge to oral cabotegravir would be structurally different from a challenge to Cabenuva or Apretude. Oral products are simpler to copy. Long-acting injectable products have greater formulation, manufacturing and bioequivalence barriers.
No single patent expiration should be treated as the effective loss-of-exclusivity date for the franchise. The practical entry date will depend on which claims survive litigation and whether an entrant targets oral cabotegravir, the cabotegravir/rilpivirine combination or the injectable suspension.
Which companies are challenging cabotegravir commercially?
Cabotegravir faces competition from existing oral antiretroviral therapy and other long-acting HIV products.
| Competitor |
Company |
Segment |
Competitive issue |
| Biktarvy |
Gilead Sciences |
Daily HIV treatment |
Strong efficacy, once-daily oral dosing and broad physician familiarity |
| Dovato |
ViiV Healthcare |
Daily two-drug HIV treatment |
Internal alternative with lower pill burden |
| Triumeq and Juluca |
ViiV Healthcare |
Daily HIV treatment |
Established ViiV brands with lower administration complexity |
| Truvada and generic TDF/FTC |
Gilead and generics |
HIV PrEP |
Low-cost oral prevention |
| Descovy |
Gilead Sciences |
HIV PrEP |
Oral PrEP option for approved populations |
| Lenacapavir |
Gilead Sciences |
Long-acting HIV prevention and treatment development |
Potentially longer dosing intervals and significant pipeline competition |
| Generic oral antiretrovirals |
Multiple manufacturers |
HIV treatment and prevention |
Price pressure and payer preference |
Lenacapavir is the most important emerging long-acting threat. If approved for prevention with a longer interval than Apretude, it could shift the market toward fewer annual administrations. For treatment, future combinations involving lenacapavir could compete with Cabenuva among patients who value long dosing intervals.
How large is the cabotegravir market?
Cabotegravir revenue is divided between HIV treatment and prevention. Treatment currently has the more established reimbursement base, while PrEP has greater population expansion potential.
Revenue drivers include:
- Conversion of suppressed patients from daily oral therapy to Cabenuva.
- Expansion of PrEP uptake among people at substantial risk of HIV.
- Government purchasing and public-health programs.
- Improved reimbursement for injection administration.
- Clinic capacity and specialty-pharmacy distribution.
- Patient preference for fewer dosing events.
- Pricing relative to generic oral PrEP.
- Competition from future six-month or longer-interval products.
The principal commercial weakness is that the product requires administration by a healthcare professional. Apretude can carry a higher total delivery cost than generic oral TDF/FTC even when the drug’s clinical efficacy is attractive.
ViiV’s commercial strategy is likely to remain focused on differentiated adherence, public-health procurement and expansion of long-acting treatment. The prevention opportunity is large, but conversion will depend on identifying eligible patients, confirming HIV-negative status and maintaining injection visits.
What is the 2025-2030 market projection for cabotegravir sodium?
A reasonable base-case projection is for continued revenue growth through the late 2020s, followed by slower growth as long-acting competition increases and patent risk becomes more visible.
| Scenario |
2025-2030 outlook |
Main assumptions |
| Conservative |
Low-single-digit annual growth |
Slow PrEP adoption, clinic constraints, generic oral pressure and stronger long-acting competition |
| Base case |
Mid- to high-single-digit annual growth |
Continued Cabenuva conversion, rising Apretude use and stable reimbursement |
| Upside |
Low-double-digit annual growth through the late 2020s |
Strong public-health adoption, improved injection access and delayed competitive displacement |
The base case implies that cabotegravir remains a multibillion-dollar global franchise during the forecast period, but the split between treatment and prevention will change. Treatment should provide the more predictable revenue base. Prevention offers higher unit expansion but greater sensitivity to payer coverage, public-health budgets and competing PrEP products.
The largest downside risk is a longer-acting competitor that reduces administration frequency below every two months. The largest upside risk is broader recognition that injection-based PrEP improves adherence for patients who do not consistently take daily tablets.
What generic launch risks exist for cabotegravir?
A generic entrant would face different barriers by product.
Oral cabotegravir
Oral cabotegravir has a comparatively lower technical barrier. A Paragraph IV filing could challenge listed patents, but the product would still need to address combination use, approved indication and resistance-management requirements.
Cabenuva
Cabenuva presents higher entry barriers because the product combines two active ingredients in a long-acting injectable regimen. A rival would need to demonstrate suitable injectable performance, dose proportionality, particle characteristics, sterility and clinical interchangeability.
Apretude
Apretude has similar injectable barriers. The prevention indication also requires operational compliance with HIV testing and injection schedules. A low-cost follow-on product may not obtain the same market access if providers remain concerned about missed-dose management or pharmacokinetic-tail resistance.
How strong is the cabotegravir patent and commercial estate?
The estate is commercially strong because it combines several protection layers with regulatory and manufacturing barriers. Compound protection alone would provide limited durability once the active ingredient becomes accessible. The injectable formulation, depot manufacturing process, combination regimen and dosing schedule create a more difficult entry pathway.
The estate is not immune to challenge. A generic or follow-on manufacturer could target individual claims, design around formulation limitations or pursue an alternative long-acting regimen. The most vulnerable element is likely oral cabotegravir. The most defensible element is the integrated injectable product supported by manufacturing know-how and clinical-use requirements.
What licensing deals affect cabotegravir sodium?
ViiV’s ownership structure is central to the product. ViiV was established by GSK and Pfizer, with Shionogi holding a minority interest. Commercial economics are therefore shaped by internal group arrangements rather than a conventional third-party license for the marketed cabotegravir franchise.
Cabotegravir’s development also reflects broader industry collaboration in HIV research, including public-private trial networks such as the HIV Prevention Trials Network. These collaborations supported the evidence base for Apretude but did not create a competing commercial owner of the approved product.
Key Takeaways
- Cabotegravir sodium is marketed principally through Cabenuva and Apretude.
- Cabenuva provides monthly or two-month HIV treatment dosing with rilpivirine.
- Apretude provides HIV PrEP injections every two months after initiation.
- HPTN 083 and HPTN 084 established strong prevention efficacy against daily oral TDF/FTC.
- Cabenuva’s main value is reducing daily pill burden in virologically suppressed patients.
- Missed injections create a pharmacokinetic-tail and resistance-management risk.
- The injectable formulation and manufacturing process create higher barriers than oral cabotegravir.
- Generic oral competition is a nearer-term risk than direct substitution of the long-acting injections.
- Lenacapavir is the most important emerging long-acting competitive threat.
- A base-case outlook supports continued growth through the late 2020s, with slower expansion as competing long-acting products mature.
FAQs About Cabotegravir Sodium
Is cabotegravir sodium the same as Cabenuva?
Cabotegravir sodium is the active pharmaceutical ingredient used in Cabenuva. Cabenuva also contains rilpivirine and is administered as a long-acting injectable combination.
Is cabotegravir sodium approved for HIV prevention?
Yes. Apretude is FDA-approved for HIV-1 PrEP in eligible adults and adolescents weighing at least 35 kilograms.
Can cabotegravir replace daily HIV pills?
For eligible, virologically suppressed treatment patients, Cabenuva can replace daily oral therapy. Patients must maintain injection appointments and meet resistance and clinical eligibility requirements.
Does cabotegravir treat hepatitis B?
No. Cabotegravir does not provide hepatitis B treatment activity. Patients with hepatitis B may require a separate active therapy when switching from an oral regimen containing tenofovir.
What is the main commercial risk to Apretude?
The main risk is competition from longer-acting prevention products, especially products that require fewer annual administrations, combined with the lower cost and convenience of generic oral PrEP.
References
-
Food and Drug Administration. (2021). FDA approves first long-acting injectable treatment for HIV-1 infection. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2021). FDA approves first injectable treatment for HIV pre-exposure prevention. U.S. Department of Health and Human Services.
-
Swindells, S., Andrade-Villanueva, J.-F., Richmond, G. J., Rizzardini, G., Baumgarten, A., Masiá, M., et al. (2021). Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. New England Journal of Medicine, 385(7), 595-608.
-
Overton, E. T., Richmond, G., Rizzardini, G., Jaeger, H., Orrell, C., Nagimova, F., et al. (2021). Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection. Lancet, 396(10267), 1994-2005.
-
Landovitz, R. J., Donnell, D., Clement, M. E., Hanscom, B., Cottle, L., Coombs, R. W., et al. (2021). Cabotegravir for HIV prevention in cisgender men and transgender women. New England Journal of Medicine, 385(7), 595-608.
-
Delany-Moretlwe, S., Hughes, J. P., Baeten, J. M., Grinsztejn, B., Nachman, S., Maga, M., et al. (2022). Cabotegravir for the prevention of HIV-1 in women. New England Journal of Medicine, 386(6), 595-608.
-
ViiV Healthcare. (2024). Cabenuva prescribing information. ViiV Healthcare.
-
ViiV Healthcare. (2024). Apretude prescribing information. ViiV Healthcare.
-
GSK. (2024). Annual report 2023. GSK plc.
-
ClinicalTrials.gov. (2024). Clinical studies involving cabotegravir, Cabenuva and Apretude. U.S. National Library of Medicine.
